Vernakalant
From Self-sufficiency
| File:Vernakalant.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
(3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl) ethoxy]cyclohexyl}pyrrolidin-3-ol | |
| Clinical data | |
| Routes of administration | Intravenous, oral |
| Identifiers | |
| CAS Number | 794466-70-9 748810-28-8 (HCl) |
| ATC code | none |
| PubChem | CID 9930049 |
| Chemical data | |
| Formula | C20H31NO4 |
| Molar mass | 349.464 g/mol[[Script error: No such module "String".]] |
Vernakalant (INN; codenamed RSD1235, proposed tradenames Kynapid or Brinavess) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation.
It is being developed by Cardiome Pharma Corp.
On December 11, 2007, the Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration voted to recommend the approval of vernakalant.[1]
An oral formulation is currently undergoing Phase II clinical studies.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." /> |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- ↑ "FDA Advisory Committee Recommends Approval of Kynapid for Acute Atrial Fibrillation". Drugs.com. Retrieved 2008-03-15.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Pharmacology stubs
- Antiarrhythmic agents
- Phenol ethers
- Pyrrolidines
- Alcohols
- 2Fix
